{"url_path":"/sec/pdsb/8-k/2026-06-02/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-023698-index.html","accession_number":"0001140361-26-023698","cik":"0001472091","ticker":"PDSB","issuer_name":"PDS Biotechnology Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-023698-index.html","primary_entity_key":"0001472091","primary_entity_name":"PDS Biotechnology Corp"},"word_count":166,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\n \n\nAs previously disclosed, on February 25, 2026, PDS Biotechnology Corporation (the “Company”) received a deficiency letter from the\nNasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per\nshare required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).\n\nOn June 2, 2026, the Company received written notice from Nasdaq informing the Company that it has regained compliance with the\nMinimum Bid Price Requirement and that Nasdaq has closed the matter.\n\nSignature\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its\nbehalf by the undersigned hereunto duly authorized.\n\n \n\nPDS BIOTECHNOLOGY CORPORATION\n\n \n\n \n\nDate: June 2, 2026\n\nBy:\n\n/s/ Frank Bedu-Addo, Ph.D.\n\n \n\nName: Frank Bedu-Addo, Ph.D.\n\n \n\nTitle: President and Chief Executive Officer"}